Live Breaking News & Updates on Arbutu Annual Report

Stay updated with breaking news from Arbutu annual report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

03.08.2023 - Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase . ....

United States , New Zealand , Lisam Caperelli , Melissav Rewolinski , N Acetylgalactosamine Galnac , William Collier , Elizabeth Howard , Karen Sims , World Health Organization , Drug Administration , Securities Exchange , Arbutus Biopharma Corporation Nasdaq , Clinical Development , Roivant Sciences Ltd , Device Safety Authority Medsafe , Institute For Health Metrics , Webcast Today , Biopharma Corporation , Arbutus President , Chief Executive , European Association , Investigational New Drug , New Zealand Medicine , Medical Device Safety Authority , Chief Medical , Vice President ,

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target. ....

United States , William Collier , Lisam Caperelli , Melissav Rewolinski , Chemical Development Group Leader , Rice University , Securities Exchange , Development For Amira Pharmaceuticals , Lannett Company Inc , Arbutus Biopharma Corporation Nasdaq , Biopharma Corporation , Arbutus Board , Chief Executive Officer , Senior Vice President , Technical Operations , Senior Director , Amira Pharmaceuticals , Pharmaceutical Sciences Project Team Leader , Lannett Company , American Type Culture Collection , Looking Statements , Securities Act , Securities Exchange Act , Arbutu Annual Report , Arbutu Quarterly Reports ,

Arbutus Appoints Two New Executives

Arbutus Appoints Two New Executives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , University College , New South Wales , Karen Sims , Lisam Caperelli , Christopher Naftzger , William Collier , Elizabeth Howard , Clinical Development , University Of Pennsylvania School Medicine , Koch Industries , Blank Rome , Arbutus Biopharma Corporation Nasdaq , Securities Exchange , World Health Organization , University Of Pennsylvania , Unilife Medical Solutions , Hospital Of The University Pennsylvania , Chesapeake Corporation , Willamette University College Of Law , Sydney College , Psychology At Bates College , Phd Promoted , Chief Medical , Naftzger Appointed , General Counsel ,

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company. | June 21, 2023 ....

United States , N Acetylgalactosamine Galnac , Lisa Caperelli , William Collier , World Health Organization , Arbutus Biopharma Corporation Nasdaq , Securities Exchange , Biopharma Corporation , European Association , Chief Executive Officer , Looking Statements , Securities Act , Securities Exchange Act , Arbutu Annual Report , Arbutu Quarterly Reports , Investor Relations ,

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleoside analogues and nivolumab WARMINSTER, Pa., June 21, 2023 Arbutus Biopharma Corporation , a clinical-stage. | June 21, 2023 ....

United States , Lisam Caperelli , Karen Sims , N Acetylgalactosamine Galnac , World Health Organization , Clinical Development At Arbutus Biopharma , Arbutus Biopharma Corporation Nasdaq , Securities Exchange , Biopharma Corporation , Vice President , Clinical Development , Looking Statements , Securities Act , Securities Exchange Act , Arbutu Annual Report , Arbutu Quarterly Reports ,